Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetesMohammad Alhadj Ali, Colin Dayan, Hina Shariff et al.|Science Translational Medicine|2017Cited by 215
Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trialDanijela Tatović, Laura Cook, Ashish Marwaha et al.|Nature Medicine|2024Cited by 40